The acute impact of a hematopoietic allograft on lung function and inflammation: a prospective observational study
© Enocson et al.; licensee BioMed Central Ltd. 2013
Received: 13 September 2012
Accepted: 10 January 2013
Published: 11 January 2013
No studies have investigated the immediate impact of receiving an allogeneic hematopoietic stem cell transplant (HSCT) on pulmonary inflammation or lung function.
Using a prospective study design, we quantified the changes in these outcome measures in eligible adult individuals in the first six months after receiving an allogeneic hematopoietic stem cell transplant.
Between January 2007 and December 2008, 72 patients were eligible to participate in the cohort, and of these 68 (94%) were included in the study. Compared to baseline, pulmonary inflammation as measured by exhaled nitric oxide increased after receiving a HSCT with the largest increment seen at three months (+6.0ppb, 95%CI: +0.4 to +11.5), and this was sustained at six months. Percent predicted forced expiratory volume in one second decreased over the same period, with the largest decrease observed at six weeks (−5.9%, 95% CI: -8.9 to −2.9), and this was also sustained over a six month period. Similar associations were observed for FVC. A larger increase in exhaled nitric oxide from baseline at six weeks and three months may be associated with decreased mortality (p=0.06, p=0.04 respectively).
Our data demonstrate that recipients of an allogeneic HSCT experience an increase in biomarkers of pulmonary inflammation and a decrease in lung function in the first six months after the procedure. If independently validated in other study populations, these observations could have potential as a prognostic biomarker for this patient group.
KeywordsLung function Inflammation Haematopoietic transplant
The use of allogeneic hematopoietic stem cell transplant (HSCT) as a treatment for haematological malignancies is increasing as the benefits of this intervention are applied to a wider patient population . However, although this intervention is associated with a variety of pulmonary complications, including infection and graft-versus-host disease [2, 3], most of the available data has utilised regular lung function measures that are taken at least 6–12 months after the allograft  or retrospective clinical studies [5, 6]. These do not give a detailed picture of the early effects on the lung after receiving an allograft and in particular do not quantify pulmonary inflammation during this time period. This is important as 5-45% of deaths from allogeneic HSCT (depending on indication) occur within 100 days after receiving a HSCT  and the cause of death can often be as a result of pulmonary complications . Hence, intensive monitoring of lung physiological outcome measures may provide insights into the natural history of the impact of receiving an allogeneic HSCT on the lungs, as well as assessing if changes in respiratory function tests have prognostic value. To be applicable in the clinical setting such tests will need to be ideally readily deliverable at regular clinic visits. We thus chose spirometry (Forced Expiratory Volume in one second and Forced Vital Capacity) and exhaled nitric oxide, a measure of pulmonary inflammation, as simple measures of lung physiological health.
We have established a cohort of patients who received an allogeneic HSCT and prospectively collected data on lung function and exhaled nitric oxide to assess the impact of this intervention on pulmonary function and a biomarker of pulmonary inflammation. We have also assessed if these outcomes are associated with survival, and thus may provide a potential biomarker that could be used to stratify patients who have received a transplant.
Our study population consisted of 68 patients that had received an allogeneic haematological stem cell transplant (HSCT) in the Nottingham Regional Transplant Centre between January 2007 and December 2009 as standard treatment for their haematological disease. All adult patients who received an allogeneic stem cell transplant when staff were available for recruitment and who had post-transplant follow-up in Nottingham were eligible to participate in the study. The study was approved by the Nottingham Regional Ethics Committee, and written consent was obtained from all subjects. All myeloablative transplants received total body irradiation of 12 to 14.4 Gy and cyclophosphamide 60mg/kg x 2days while reduced intensity conditioning varied according to the clinical condition.
Approximately 1–2 weeks before the transplant, baseline data were collected on sex, age, indication for transplant and smoking history. The baseline data were collected after chemotherapy treatment had started, but prior to transplant. After transplant, the patients were assessed during their routine clinical visits to the transplant clinic at 6 weeks, 3 months and 6 months.
Pulmonary Function measurements were performed using a Vitalograph 2120 spirometer (Vitalograph Ltd, Buckingham, England). Forced vital capacity in one second (FEV1) and Forced Vital Capacity (FVC), were measured according to ERS/ATS criteria , and compared with predicted values from the European Community for Steel and Coal normal range . Fractional exhaled nitric oxide (FENO) measurements were made using an NIOX MINO portable analyser (Aerocrine AB, Stockholm, Sweden), an electrochemical analyser, at a sample rate of 50 mL/min. FENO measurements were performed prior to spirometry. Patients were instructed not to eat or drink for a minimum of one hour prior to testing. Patients were seated at rest, for at least 20 min prior to the test and results were recorded in parts per billion (PPB). The initial study proposal aimed to look at the short-term changes in lung function after receiving an allograft HSCT, and we were subsequently also able to later collect data on pulmonary inflammation after starting data collection.
The data were analysed using Cox Regression to assess the association of the lung measurements with subsequent survival. As well as presentation of mean changes in lung function and exhaled nitric oxide as measured by paired t-tests, the proportion of individuals whose lung function decreased by more than 15% or whose exhaled nitric oxide increased by 10ppb or more are presented, to give a more complete presentation of those who experienced large changes in the pulmonary measures of interest. The start time for the survival analysis was the date of the HSCT and the final date was the last date when the individual was followed up in clinic or the date of death. In the survival analysis, sex, age and smoking status were added to the model as a priori potential confounding factors. The proportional hazards assumption for the survival analysis was tested to ensure that these were not contravened. All statistical analyses were done utilising STATA 11.0 (Texas, USA). The numbers of patients followed up decreased with time as a consequence of mortality.
Characteristics of the allograft recipients in the study
Total no. of individuals in cohort
Mean age at transplant, sd
48.5 years (13.2)
Smoking status (%)
Diagnosis at HSCT (%)
Non Hodgkin’s Lymphoma
Chronic lymphatic leukaemia
Donor type (%)
Matched unrelated donor
Stem Cell Source (%)
Peripheral blood stem cell source
Type of Conditioning prior to HSCT (%)
Change in lung function and pulmonary inflammation occurring after receiving an allograft haematopoietic stem cell transplant
Time after stem cell transplant
Mean percent predicted FEV1 (sd)
Change in percent predicted FEV1 from baseline (95% CI)
(−8.9 to −2.9)
(−8.4 to −1.0)
(−7.7 to −0.9)
Number with decrease in predicted FEV1 by ≥15% (%)
Mean percent predicted FVC (sd)
Change in FVC from baseline
(−9.7 to −3.0)
(−9.1 to −1.5)
(−9.1 to −2.2)
Number with decrease in predicted FVC by ≥15% (%)
Median exhaled nitric oxide, ppb, (IQR)
Change in exhaled nitric oxide from baseline, ppb (95% CI)
(−1.8 to +5.9)
(+0.4 to +11.5)
(+0.7 to +12.1)
Number with increase in exhaled NO by ≥10ppb (%)
Subgroup comparison between those who received full myloablative conditioning and those who received reduced intensity conditioning for revealed no consistent differences between the two groups for lung function or exhaled nitric oxide, although at three months those who received the reduced intensity conditioning had a smaller decrease in both FEV1 (+7.6%; 95%CI: +0.1 to +15.2) and FVC (+9.4; 95%CI: +1.6 to +17.1) compared to those who did not receive reduced intensity conditioning.
In the survival analysis, there were 22942 days of total analysis time at risk and 22 deaths during this period. After adjustment for sex, age and smoking status, there was an inverse association between change in exhaled NO from baseline to six weeks and risk of death (Hazard Ratio HR 0.95 per unit of exhaled NO, 95% CI: 0.90 to 1.00, p=0.06) and three months (HR 0.94 per unit of exhaled NO, 95% CI: 0.89 to 1.00, p=0.04) for those individuals who provided paired data. There was no association between risk of death and change in lung function at the same time points after adjusting for the same covariates (data not shown).
This is the first study to explore the early changes in lung function and pulmonary inflammation in a cohort of individuals who had undergone an allogeneic hematopoietic stem cell transplant. Our data demonstrate that lung function decreases and pulmonary inflammation increases after receiving an allogeneic HSCT. The change in exhaled nitric oxide may have potential in the stratification of patients for subsequent risk of mortality, and we consider that this is worth consideration in future cohort studies assessing potential biomarkers in this patient group.
One strength of our data is its high response rate, with 94% of eligible patients being enrolled in the cohort and only 6% of eligible patients declining to provide data. We were subsequently able to follow up the patients and collect detailed information on their changes in lung function and pulmonary inflammation, and also collect data on potential confounding factors and mortality. As our measurements were collected by a single person in a standardised manner, we are confident in that we have minimised the bias that can be introduced by multiple observers collecting data. The collection of data from a single centre which all patients who live in the surrounding centre attend ensures that the mortality data is complete.
Our study has a variety of limitations that require consideration. Having elected to collect detailed data on lung function and pulmonary inflammation, the study necessarily had to be from only one transplant centre due to staffing constraints. This has limited the number of participants that we were able to recruit and hence the power of the study to detect clinically important associations. However, this is the largest study to measure lung function and pulmonary inflammation in this patient cohort during the early months after receiving an allogeneic HSCT, and the 95% confidence intervals in our data should be useful in guiding researchers and clinicians in the future of the potential of these outcome measures in managing these patients. Unfortunately, we were unable to collect more detailed data on lung function including transfer factor due the logistical challenges of doing time-intensive measurements in a group of patients who are already debilitated from the HSCT. The generalisability of these data should be good for populations that are similar in age, initial disease and HSCT treatment regimens. As we have a relatively small study population and have tested a number of hypotheses, we are unable to exclude the possibility that some of the apparently significant associations observed may be spurious as a consequence of multiple hypothesis testing.
Previous research on the impact of receiving an allogeneic HSCT has tended to use routinely collected data at clinic visits, which is a powerful approach allowing over time large numbers of data to be collected. The largest previous study by Chien et al. demonstrated that new airflow obstruction (as defined as a more than 5% annual decline in FEV1 with the lowest post-transplant FEV1/FVC ratio of less than 0.8) was 26%, and associated with higher mortality rates at follow up than those with no airflow obstruction . However, this important study did not look at pulmonary function tests within 6 months of receiving a HSCT, and hence is not directly comparable with our data. Savani et al. studied patients who survived for five years or more after HSCT, and reported that chronic graft-versus-host disease (GVHD) and low FEV1 and diffusion capacity for carbon monoxide were associated with a decrease in pulmonary function. As this study described a survivor cohort with a long follow up period, again direct comparisons with our data are impossible. Similarly, Lund et al. studied 43 patients who survived for five years and reported a decrease in lung function and transfer factor in the first year which returned to baseline after five years, and again these data are hence in a survivor cohort and not directly comparable to our data. A recent study looking at 33 patients, approximately one year after HSCT suggested that peripheral airways heterogeneity may be a better measure that could be more sensitive than simple lung function measurements such as FEV1 in detecting early lung pathology .
To our knowledge no other studies have looked at the impact of receiving an allogeneic HSCT on pulmonary inflammation in adults in the six months after the procedure. The increase in pulmonary inflammation observed after HSCT may be a consequence of either the conditioning or the result of an immunological or inflammatory response to the allograft, and the absence of a consistent difference between the two conditioning groups suggests that the latter explanation may be more likely, although the study was not powered to examine these differences. The inverse association between change in exhaled NO from baseline at six weeks and three months with subsequent mortality was unexpected and needs to be considered with caution as the numbers of patients studied were small and these relationships may have occurred by chance as we have tested a number of associations in this analysis (p=0.04 to 0.06). Nonetheless, this is an interesting observation worth consideration. Exhaled nitric oxide is a measure of pulmonary inflammation , and the inflammatory response in general probably evolved to help host organisms fight infection . A recent study in 30 children with a mean age of 12 years suggests that higher exhaled nitric oxide is associated with pulmonary complications (predominantly infections) 28 days after receiving a HSCT , demonstrating that this biological response is active in the early period after receiving a HSCT. Hence, we cautiously speculate that the inverse association between change in pulmonary inflammation and mortality observed in our dataset, if a true phenomenon, may be a consequence of an impaired ability to generate an inflammatory response, which may then result in increased susceptibility to infections in this patient group.
By adding to the literature of the relatively short-term consequences of receiving an allogeneic HSCT on the lungs, we have observed associations and hence generated hypotheses that now require consideration in other populations. The identification of biomarkers for pulmonary disease and mortality in individuals who have received an allogeneic HSCT is important as it will allow the early identification of those who are at high risk for these complications. This can then permit more intensive monitoring of this patient group and possibly also stratification to allow better targeted trials of interventions that can modify disease progression without exposing individuals who are less likely to develop these complications to the potential adverse side-effects that can accompany many therapeutic interventions.
In summary, we have demonstrated in a representative sample of patients who received an allogeneic HSCT that pulmonary inflammation increases in the first six months after the procedure while lung function decreases over the same time period. We hope that future research in this area will examine these associations in larger numbers of patients that will provide more power to determine the clinical importance of these associations.
Forced Expiratory Volume in one second
Forced Vital Capacity
Human stem cell transplant
Thanks to all the staff and patients of the Nottingham University Hospital bone marrow transplantation clinic. This work was funded by University of Nottingham, and Nottingham University Hospitals Charity.
This work was funded by University of Nottingham, and Nottingham University Hospitals Charity.
- Copelan E: Hematopoietic stem-cell transplantation. New Eng J Med. 2006, 354: 1813-1826. 10.1056/NEJMra052638.PubMedView Article
- Williams K, Chien J, Gladwin M, Pavletic S: Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009, 302: 306-314. 10.1001/jama.2009.1018.PubMedView Article
- Ferrara J, Levine J, Reddy P, Holler E: Graft-versus-host disease. Lancet. 2009, 373: 1550-1561. 10.1016/S0140-6736(09)60237-3.PubMedPubMed CentralView Article
- Chien J, Martin P, Gooley T, Flowers M, Heckbert S, et al: Airflow obstruction after myeloablative allogeneic hematopoeitic stem cell transplantation. Am J Respir Crit Care Med. 2003, 168: 208-214. 10.1164/rccm.200212-1468OC.PubMedView Article
- Lund M, Brinch L, Kongerud J, Boe J: Lung function 5 years after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Resp J. 2004, 23: 901-905. 10.1183/09031936.04.00084804.View Article
- Parimon T, Madtes D, Au D, Clark J, Chien J: Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med. 2005, 172: 384-390. 10.1164/rccm.200502-212OC.PubMedPubMed CentralView Article
- Ho V, Weller E, Lee S, Alyea E, Antin J, et al: Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplantation. 2001, 7: 223-229. 10.1053/bbmt.2001.v7.pm11349809.View Article
- Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al: Standardisation of spirometry. Eur Resp J. 2005, 26: 319-338. 10.1183/09031936.05.00034805.View Article
- Quanjer P, Tammeling G, Cotes J, Pedersen O, Peslin R, et al: Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Resp J. 1993, 6: 41-52.View Article
- Savani B, Montero A, Srinivasan R, Singh A, Shenoy A, et al: Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplantation. 2006, 12: 1261-1269. 10.1016/j.bbmt.2006.07.016.View Article
- Lahzami S, Schoeffel R, Pechey V, Reid C, Greenwood M, et al: Small airways function declines after allogenic haematopoetic stem cell transplantation. Eur Resp J. 2011, 38: 1180-1188. 10.1183/09031936.00018311.View Article
- Ricciardolo F: Multiple roles of nitric oxide in the airways. Thorax. 2003, 58: 175-182. 10.1136/thorax.58.2.175.PubMedPubMed CentralView Article
- Medzhitov R: Origin and physiological roles of inflammation. Nature. 2008, 454: 428-435. 10.1038/nature07201.PubMedView Article
- Fazekas T, Eickhoff P, Lawitschaka A, Knotek B, Potschger U, et al: Exhaled nitric oxide and pulmonary complications after paediatric stem cell transplantation. Eur J Pediatr. 2012, 171: 1095-1101. 10.1007/s00431-012-1692-x.PubMedView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/13/2/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.